

DAFTAR PUSTAKA

A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*, 77(1), 1–15 | 10.1016/j.diabres.2006.10.015 [Internet]. Hkvisa.net. 2022 [cited 2022 Jan 5]. Available from: [https://sci-hub.hkvisa.net/https://www.diabetesresearchclinicalpractice.com/article/S0168-8227\(06\)00486-4/fulltext](https://sci-hub.hkvisa.net/https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(06)00486-4/fulltext)

Abreu M, Tumyan A, Elhassan A, Peicher K, Papacostea O, Dimachkie P, Siddiqui MS, Pop LM, Gunasekaran U, Meneghini LF, Adams-Huet B, Li X, Lingway I. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. *Diabetes Obes Metab*. 2019 Sep;21(9):2133-2141. doi: 10.1111/dom.13794. Epub 2019 Jun 28. PMID: 31144435.

Anyanwagu, U., Mamza, J., Gordon, J., Donnelly, R. and Idris, I. (2017). Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. *Diabetic Medicine*, 34(12), pp.1728–1736.

Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, Casal F, Delgado E, Menendez E, Umpierrez GE. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. *Diabetes Care*. 2015 Dec;38(12):2211-6. doi: 10.2337/dc15-0160. Epub 2015 Oct 12. PMID: 26459273; PMCID: PMC4657612.

Blonde L, Baron MA, Zhou R, Banerji MA. Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors.

Postgraduate Medicine [Internet]. 2014 May [cited 2022 Jan 5];126(3):172–89.

Available from: <https://pubmed.ncbi.nlm.nih.gov/24918802/>

Candido, R., Wyne, K. and Romoli, E. (2018). A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of diabetes melitus. Diabetes Therapy, [online] 9(3), pp.927–949. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984925/> [Accessed 12 Jan. 2021].

CDC. Diabetes Risk Factors. Centers for Disease Control and Prevention. Published April 23, 2021. Accessed September 1, 2021. <https://www.cdc.gov/diabetes/basics/risk-factors.html>

Chaikiat Å, Li X, Bennet L, Sundquist K. Neighborhood deprivation and inequities in coronary heart disease among patients with diabetes melitus: A multilevel study of 334,000 patients. Health & Place. 2012;18(4):877-882. doi:10.1016/j.healthplace.2012.03.003

Dan, P., Diabetes, P. and Tipe, M. (2015). PERKUMPULAN ENDOKRINOLOGI I N D O N E S I A P E R K E N I P E R K E N I P E R K E N I KONSENSUS. [online] Available at: <https://pbperkeni.or.id/wp-content/uploads/2019/01/4.-Konsensus-Pengelolaan-dan-Pencegahan-Diabetes-melitus-tipe-2-di-Indonesia-PERKENI-2015.pdf>.

De la Pena A, Riddle M, Morrow LA, et al. Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care. 2011;34(12):2496-2501. doi:10.2337/dc11-0721

Diabetes and cardiovascular disease prevention. Vic.gov.au. Published 2012. Accessed August 31, 2021. <https://www2.health.vic.gov.au/public-health/preventive-health/diabetes-and-cardio-vascular-disease-prevention>

Donner, T. and Sudipa Sarkar (2019). Insulin – Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy. [online] Nih.gov. Available at: https://www.ncbi.nlm.nih.gov/books/NBK278938/#insulin-pharmacology.TYPES_OF_REGIMENS [Accessed 7 Jan. 2021].

Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes, Obesity and Metabolism. 2011;14(3):228-233. doi:10.1111/j.1463-1326.2011.01512.x

Europe PMC. Europe PMC. Europepmc.org. Published 2016. Accessed August 31, 2021. <https://europepmc.org/article/med/21536829>

Fritsche A, Larbig M, Owens D, Häring H-U . Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes, Obesity and Metabolism [Internet]. 2010 Feb [cited 2022 Jan 5];12(2):115–23. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1463-1326.2009.01165.x>

Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics—2014 Update. Circulation. 2014;129(3). doi:10.1161/01.cir.0000441139.02102.80

Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet. 2014;383(9922):1068-1083. doi:10.1016/s0140-6736(13)62154-6

Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 diabetes melitus. *Endocrine Reviews*. 2016;37(3):278-316. doi:10.1210/er.2015-1137

Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. *Pharmacological Research*. 2018;129:95-99. doi:10.1016/j.phrs.2017.11.003

Kumar, A. and Cannon, C.P. (2009). Acute coronary syndromes: diagnosis and management, part I. *Mayo Clinic proceedings*, [online] 84(10), pp.917–38. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755812/> [Accessed 2 Jun. 2021].

Lee, A.K., Juraschek, S.P., Windham, B.G., Lee, C.J., Sharrett, A.R., Coresh, J. and Selvin, E. (2020). Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care*, [online] 43(9), pp.2060–2065. Available at: <https://care.diabetesjournals.org/content/43/9/2060> [Accessed 7 Jan. 2021].

Mellbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. *European Heart Journal* [Internet]. 2013 Sep 2 [cited 2022 Jan 5];34(40):3137–44. Available from: <https://pubmed.ncbi.nlm.nih.gov/23999452/>

Miyoshi H, Baxter M, Kimura T, Hattori M, Morimoto Y, Marinkovich D, et al. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes. *Diabetes Therapy* [Internet]. 2021 Mar 17 [cited 2022 Jan 5];12(5):1341–57. Available from: <https://link.springer.com/article/10.1007/s13300-021-01041-x>

Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of

Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2008;32(1):193-203. doi:10.2337/dc08-9025

Ndraha, S. (2014) 'Diabetes Melitus tipe II Dan Tatalaksana Terkini', 27(2), pp. 9–16.

Nimri, R., Nir, J. and Phillip, M. (2020). Insulin Pump Therapy. *American Journal of Therapeutics*, [online] 27(1), pp.e30–e41. Available at: <https://pubmed.ncbi.nlm.nih.gov/31833871/> [Accessed 13 Jan. 2021].

North BJ, Sinclair DA. The Intersection Between Aging and Cardiovascular Disease. *Circulation Research*. 2012;110(8):1097-1108. doi:10.1161/circresaha.111.246876

Penatalaksanaan diabetes melitus terpadu : panduan penatalaksanaan diabetes melitus bagi dokter dan edukator , Dr. Imam Subekti, SpPD-KEMD. | OPAC Perpustakaan Nasional RI. Perpustnas.go.id. Published 2018. Accessed August 31, 2021. <https://opac.perpusnas.go.id/DetailOpac.aspx?id=1145474>

Penatalaksanaan keperawatan diabetes melitus terpadu : dengan penerapan teori keperawatan self care orem / Ernawati | OPAC Perpustakaan Nasional RI. Perpustnas.go.id. Published 2013. Accessed August 31, 2021. <https://opac.perpusnas.go.id/DetailOpac.aspx?id=992311>

Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents. *Diabetes Care* [Internet]. 2008 Jan 1 [cited 2022 Jan 5];31(1):20–5. Available from: <https://diabetesjournals.org/care/article/31/1/20/27923/Advancing-Insulin-Therapy-in-Type-2-Diabetes>

Segala sesuatu yang harus anda ketahui tentang diabetes : panduan lengkap mengenal dan mengatasi diabetes dengan cepat dan mudah / Hans Tandra | OPAC Perpustakaan

Nasional RI. Perpustnas.go.id. Published 2018. Accessed August 31, 2021.

<https://opac.perpustnas.go.id/DetailOpac.aspx?id=1045509>

Smeltzer, S. C., Bare, B. G., Hinkle, J. L., Cheever, K. H., Townsend, M. C., & Gould, B. (2008). *Brunner and Suddarth's textbook of medicalsurgical nursing 10th edition*. Philadelphia: Lipincott Williams & Wilkins.

Standards of Medical Care in Diabetes--2010. *Diabetes Care*. 2009;33(Supplement_1):S11-S61. doi:10.2337/dc10-s011

Tandra, H. (2017) *Segala Sesuatu yang Harus Anda Ketahui Tentang Diabetes - Hans Tandra* - Google Buku. Available at: https://books.google.co.id/books?hl=id&lr=&id=espGDwAAQBAJ&oi=fnd&pg=PP1&dq=pengertian+diabetes+menurut+idf&ots=VsK8oZmJg4&sig=BCsKUoUDCNDE6NAX5JmkneRf1Y&redir_esc=y#v=onepage&q=pengertian+diabetes+menurut+idf&f=false (Accessed: 18 August 2018).

Wong, N.D., Zhao, Y., Patel, R., Patao, C., Malik, S., Bertoni, A.G., Correa, A., Folsom, A.R., Kachroo, S., Mukherjee, J., Taylor, H. and Selvin, E. (2016). Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. *Diabetes Care*, [online] 39(5), pp.668–676. Available at: <https://care.diabetesjournals.org/content/39/5/668> [Accessed 7 Jan. 2021].

World Health Organization: WHO. Cardiovascular diseases (CVDs). Who.int. Published June 11, 2021. Accessed August 31, 2021. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))

